This is an exciting era for translational research, with novel therapeutic and diagnostic approaches for a wide spectrum of diseases, including diseases of the eye. Translational research, the conversion of basic science discoveries into clinical applications, inevitably includes issues regarding the commercialization process. Since the Bayh-Dole Act of 1980, the line of demarcation between the domains of the nonprofit academic institution and the commercial world has become increasingly fuzzy. A recent case example provides an illustration of this blurring and the potential effects of institutional conflict of interest.
McKinney RE. Institutional Conflict of Interest and the Translational Pathway. JAMA Ophthalmol. 2016;134(5):483-484. doi:10.1001/jamaophthalmol.2016.0459